We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$435M
AUM Growth
+$106M
Cap. Flow
+$33.1M
Cap. Flow %
7.6%
Top 10 Hldgs %
83.67%
Holding
29
New
6
Increased
6
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$51.9M
2
UTHR icon
United Therapeutics
UTHR
+$41.1M
3
MRK icon
Merck
MRK
+$36.8M
4
VERA icon
Vera Therapeutics
VERA
+$18M
5
AXSM icon
Axsome Therapeutics
AXSM
+$15.1M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.2M
3
VRNA
Verona Pharma
VRNA
+$20.5M
4
INSP icon
Inspire Medical Systems
INSP
+$19.4M
5
UNH icon
UnitedHealth
UNH
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
26
Teva Pharmaceuticals
TEVA
$40.7B
– –
-2,046,846
Closed -$34.3M
UNH icon
27
UnitedHealth
UNH
$374B
– –
-60,584
Closed -$18.9M
VRNA
28
DELISTED
Verona Pharma
VRNA
– –
-216,578
Closed -$20.5M
WGS icon
29
GeneDx Holdings
WGS
$2.13B
– –
-32,931
Closed -$3.04M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Tri Locum Partners held 29 positions worth $435M, up 32% from $330M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Tri Locum Partners deployed $33.1M of net new capital in Q3 2025, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was Johnson & Johnson: 302,831 shares worth $56.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $11.2M trimmed.

  • Tri Locum Partners's largest Q3 2025 buy was Johnson & Johnson: 302,831 shares worth $56.2M.
  • Tri Locum Partners added most to Vera Therapeutics in Q3 2025, an estimated $18M increase.
  • Tri Locum Partners's biggest Q3 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $11.2M.
  • Tri Locum Partners fully exited Teva Pharmaceuticals in Q3 2025, selling an estimated $34.3M.
  • Tri Locum Partners's ten largest holdings make up 84% of its $435M portfolio in Q3 2025.
  • Tri Locum Partners opened 6 new positions and closed 11 in Q3 2025.
  • Tri Locum Partners's portfolio value rose 32% quarter-over-quarter to $435M.

Based on Tri Locum Partners's 13F filing for Q3 2025, filed 14 Nov 2025.